Ascletis Pharma Inc. (HKG:1672)
14.90
-0.44 (-2.87%)
At close: Mar 13, 2026
Ascletis Pharma Market Cap
Ascletis Pharma has a market cap or net worth of 15.81 billion as of March 13, 2026. Its market cap has increased by 155.19% in one year.
Market Cap
15.81B
Enterprise Value
13.84B
Revenue
2.59M
Ranking
n/a
PE Ratio
n/a
Stock Price
14.90
Market Cap Chart
Since August 1, 2018, Ascletis Pharma's market cap has increased from 15.69B to 15.81B, an increase of 0.77%. That is a compound annual growth rate of 0.10%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 13, 2026 | 15.81B | 40.66% |
| Dec 31, 2025 | 11.24B | 287.10% |
| Dec 31, 2024 | 2.90B | 90.74% |
| Dec 29, 2023 | 1.52B | -70.46% |
| Dec 30, 2022 | 5.15B | 44.13% |
| Dec 31, 2021 | 3.58B | 13.38% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Aug 1, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Duality Biotherapeutics | 24.37B |
| Genscript Biotech | 24.25B |
| InnoCare Pharma | 23.86B |
| PegBio | 21.10B |
| Ascentage Pharma Group International | 16.76B |
| Zai Lab | 16.12B |
| Keymed Biosciences | 15.50B |
| Everest Medicines | 12.75B |